← Back to patent-cliff list
LY-4065967
Tier C — Watch / tradeLY-4065967
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT2
Indications (approved)：Low back pain, Chronic pain, Knee arthritis, Diabetic neuropathy
Regional status
US
Phase II
2026-02-16
EU
-
China
-
Japan
Phase I
2024-10-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-4065967?
Approved indications include: Low back pain, Chronic pain, Knee arthritis, Diabetic neuropathy.
When does the LY-4065967 patent expire?
No public expiry year is available for LY-4065967 yet; this page updates once verified.
How do I get a quote for LY-4065967 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29